| abstract |
The invention relates to a guanidine of the formula:- n<CHEM>n in which R<1> and R<2> are H, C1-10 alkyl, C3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C1-6 and the cycloalkyl part is C3-8, each of the alkyl, cycloalkyl and cycloalkylalkyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R<1> and R<2> is a halogen substituted alkyl, cycloalkyl or cycloalkyl-alkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen;n ring X is phenyl carrying 1 or 2 optional substitutents or a 5- or 6-membered heterocyclic aromatic ring containing 1, 2 or 3 hetero atoms selected from O, N and S, which heterocyclic ring may, carry a single optional substituent selected from F, Cl, Br, I, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, trifluoromethyl, hydroxy and amino;n Y is O, S, a direct bond, methylene, vinylene, SO or NR<4> in which R<4> is H or C1-6 alkyl;n m is 0 to 4 and n is 1 to 5, provided that when Y is O, SO or NR<4>, n is 2 to 5;n R<3> has various significances;n and the pharmaceutically-acceptable acid-addition salts thereof. n<??>Manufacturing processes and pharmaceutical compositions are also described. |